Seroatlas · Human Serome Atlas

IPO5

Importin-5

Also known as: IMB3, IPO5_HUMAN, KPNB3, MGC2068, PSE1, RANBP5

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O00410
Gene: IPO5
Ensembl: ENSG00000065150
Chromosome: 13
Canonical length: 1097 aa
Protein class: Plasma proteins, Predicted intracellular proteins, Transporters
Subcellular location: Nucleoplasm,Nuclear membrane,Golgi apparatus,Cytosol

OverviewNCBI Gene

Nucleocytoplasmic transport, a signal- and energy-dependent process, takes place through nuclear pore complexes embedded in the nuclear envelope. The import of proteins containing a nuclear localization signal (NLS) requires the NLS import receptor, a heterodimer of importin alpha and beta subunits also known as karyopherins. Importin alpha binds the NLS-containing cargo in the cytoplasm and importin beta docks the complex at the cytoplasmic side of the nuclear pore complex. In the presence of nucleoside triphosphates and the small GTP binding protein Ran, the complex moves into the nuclear pore complex and the importin subunits dissociate. Importin alpha enters the nucleoplasm with its passenger protein and importin beta remains at the pore. Interactions between importin beta and the FG repeats of nucleoporins are essential in translocation through the pore complex. The protein encoded by this gene is a member of the importin beta family. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

1097 residues, UniProt reviewed canonical sequence.

>O00410|IPO5
     1  MAAAAAEQQQ FYLLLGNLLS PDNVVRKQAE ETYENIPGQS KITFLLQAIR NTTAAEEARQ
    61  MAAVLLRRLL SSAFDEVYPA LPSDVQTAIK SELLMIIQME TQSSMRKKVC DIAAELARNL
   121  IDEDGNNQWP EGLKFLFDSV SSQNVGLREA ALHIFWNFPG IFGNQQQHYL DVIKRMLVQC
   181  MQDQEHPSIR TLSARATAAF ILANEHNVAL FKHFADLLPG FLQAVNDSCY QNDDSVLKSL
   241  VEIADTVPKY LRPHLEATLQ LSLKLCGDTS LNNMQRQLAL EVIVTLSETA AAMLRKHTNI
   301  VAQTIPQMLA MMVDLEEDED WANADELEDD DFDSNAVAGE SALDRMACGL GGKLVLPMIK
   361  EHIMQMLQNP DWKYRHAGLM ALSAIGEGCH QQMEGILNEI VNFVLLFLQD PHPRVRYAAC
   421  NAVGQMATDF APGFQKKFHE KVIAALLQTM EDQGNQRVQA HAAAALINFT EDCPKSLLIP
   481  YLDNLVKHLH SIMVLKLQEL IQKGTKLVLE QVVTSIASVA DTAEEKFVPY YDLFMPSLKH
   541  IVENAVQKEL RLLRGKTIEC ISLIGLAVGK EKFMQDASDV MQLLLKTQTD FNDMEDDDPQ
   601  ISYMISAWAR MCKILGKEFQ QYLPVVMGPL MKTASIKPEV ALLDTQDMEN MSDDDGWEFV
   661  NLGDQQSFGI KTAGLEEKST ACQMLVCYAK ELKEGFVEYT EQVVKLMVPL LKFYFHDGVR
   721  VAAAESMPLL LECARVRGPE YLTQMWHFMC DALIKAIGTE PDSDVLSEIM HSFAKCIEVM
   781  GDGCLNNEHF EELGGILKAK LEEHFKNQEL RQVKRQDEDY DEQVEESLQD EDDNDVYILT
   841  KVSDILHSIF SSYKEKVLPW FEQLLPLIVN LICPHRPWPD RQWGLCIFDD VIEHCSPASF
   901  KYAEYFLRPM LQYVCDNSPE VRQAAAYGLG VMAQYGGDNY RPFCTEALPL LVRVIQSADS
   961  KTKENVNATE NCISAVGKIM KFKPDCVNVE EVLPHWLSWL PLHEDKEEAV QTFNYLCDLI
  1021  ESNHPIVLGP NNTNLPKIFS IIAEGEMHEA IKHEDPCAKR LANVVRQVQT SGGLWTECIA
  1081  QLSPEQQAAI QELLNSA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IPO5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.23
Highest tissue expression: 196 nTPM

Expression across tissuesHPA

Tissue

testis: 196 nTPM
skeletal muscle: 127 nTPM
tongue: 108 nTPM
ovary: 63 nTPM
pancreas: 60 nTPM
heart muscle: 57 nTPM

Single-cell type

late spermatids: 3,125 nCPM
early spermatids: 1,448 nCPM
late primary spermatocytes: 586 nCPM
pancreatic acinar cells: 168 nCPM
erythrocyte progenitors: 149 nCPM
epicardial cells: 111 nCPM

Immune cell

MAIT T-cell: 12 nTPM
myeloid DC: 12 nTPM
naive CD4 T-cell: 12 nTPM
NK-cell: 12 nTPM
naive CD8 T-cell: 9.7 nTPM
T-reg: 9.3 nTPM

Brain region

cerebral cortex: 80 nTPM
white matter: 73 nTPM
basal ganglia: 68 nTPM
spinal cord: 61 nTPM
medulla oblongata: 59 nTPM
hippocampal formation: 59 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about IPO5.

Disease | ImmuneIEDB

Conditions an epitope on IPO5 was assayed in.

narcolepsy B cell
multiple sclerosis B cell
peripheral nervous system disease B cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.12
gnomAD pLI: 1
gnomAD missense Z: 3.36
DepMap mean gene effect: -0.19
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of IPO5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IPO5 as an antibody target. Whether an autoantibody or antibody against IPO5 could matter depends on whether native IPO5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IPO5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label IPO5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...